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Abstract
Background
In a systematic review and meta-analysis we summarize the available evidence on how fre-
quently general practitioners/family physicians (GPs) use pure placebos (e.g., placebo pills)
and non-specific therapies (sometimes referred to as impure placebos; e.g., antibiotics for
common cold).
Methods
We searched Medline, PubMed and SCOPUS up to July 2018 to identify cross-sectional
quantitative surveys among GPs. Outcomes of primary interest were the percentages of
GPs having used any placebo, pure placebos or non-specific therapies at least once in their
career, at least once in the last year, at least monthly or at least weekly. Outcomes were
described as proportions and pooled with random-effects meta-analysis.
Results
Of 674 publications, 16 studies from 13 countries with a total of 2.981 participating GPs
(range 27 to 783) met the inclusion criteria. The percentage of GPs having used any form
of placebo at least once in their career ranged from 29% to 97%, in the last year at least
once from 46% to 95%, at least monthly from 15% to 89%, and at least weekly from 1% to
75%. The use of non-specific therapies by far outnumbered the use of pure placebo. For
example, the proportion of GPs using pure placebos at least monthly varied between 2%
and 15% compared to 53% and 89% for non-specific therapies; use at least weekly varied
between 1% and 3% for pure placebos and between 16% and 75% for non-specific
therapies. Besides eliciting placebos effects, many other reasons related to patient expecta-
tions, demands and medical problems were reported as reasons for applying placebo
interventions.
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Conclusion
High prevalence estimates of placebo use among GPs are mainly driven by the frequent
use of non-specific therapies; pure placebos are used rarely. The interpretation of our quan-
titative findings is complicated by the diversity of definitions and survey methods.
Introduction
Although the use of placebo interventions outside clinical trials without full informed consent
is generally considered unethical [1–3], surveys in various countries show that many physi-
cians prescribe “placebos” in routine clinical practice [4–7]. A major problem when investigat-
ing the prevalence of placebo use is that it is far from clear what kind of intervention qualifies
as a placebo in routine clinical practice [8,9]. There is little disagreement about what is called
“pure placebo”, such as sugar pills or saline injections. However, placebo definitions in most
surveys also include many potentially active interventions, which are thought to have no spe-
cific activity on the condition being treated beyond a placebo effect [4–6]. These interventions
sometimes are called “impure placebos” [4,6] or “non-specific therapies” [7]. To emphasize the
clinically important difference to “pure placebos” we prefer the term “non-specific therapies”
in this report. Typical examples are antibiotics in viral infections or vitamins in patients with-
out deficiency, but some surveys also included treatments not backed up by solid evidence,
positive suggestions or non-essential physical or technical examinations.
In recent years, the use of placebos has been investigated more often among general practi-
tioners (GPs) than among any other medical disciplines [4–7,10]. It seems plausible to assume
that GPs use placebos more frequently because they see many patients with unclear, non-spe-
cific complaints or minor ailments as well as chronically ill patients coming back from special-
ists without a fully satisfying therapy. In this report, we present a systematic review and meta-
analysis of all available cross-sectional quantitative surveys on the use of placebo interventions
among general practitioners. Our objective was to summarize current knowledge on 1) the fre-
quency of use of any placebo interventions, pure placebos and non-specific therapies; 2) what
kind of placebo interventions actually are used; and 3) whether placebo use among GPs differs
from that in other medical specialties.
Methods
The methods of the review were pre-defined in a protocol (see S1 File); we have considered
registering our protocol in PROSPERO, but this register is limited to reviews with “a health
related outcome” (https://www.crd.york.ac.uk/prospero/aboutreg.php?reg=inclusioncriteria).
Selection criteria, literature search and selection process
To be included, studies had to be cross-sectional quantitative surveys among GPs (defined as
physicians explicitly described as GPs or family physicians, or in countries without such a spe-
cialization primary care physicians seeing unselected adult patients or patients of any age).
Surveys in mixed samples of physicians were included if separate subgroup data on GPs was
reported in the publication or could be obtained from authors or from re-analyses of the raw
data. For inclusion in our review, publications also had to report numerical results on the use
of any placebo intervention, or pure placebos, or non-specific therapies. We used the following
definitions for our key terms: placebo interventions—any intervention considered a placebo
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(pure or impure) in a primary study. Pure placebos—any products such as placebo tablets or
pure placebo pills without active agent and manufactured to be a placebo intervention; saline
injections or infusions provided as placebos. Non-specific therapies (= impure placebo)—“pla-
cebo” interventions other than pure placebos, e.g. antibiotics in viral infections not considered
indicated by the provider.
The main electronic literature searches were performed in February 2017 in PubMed, Med-
line (using Web of Science) and Scopus (see S2 File for detailed strategies). PubMed was
searched using a strategy combining a subject term (“placebo” in title), a combination of
design terms (“survey” and related terms) and a combination of field terms (“general practice”
and related terms). As this strategy failed to identify two relevant surveys known to the
authors, an additional Medline search focusing mainly on title words (excluding publications
likely to be placebo-controlled trials) was performed. Scopus was searched using a similar
strategy. In addition, citation searches were done in Google Scholar for four key publications
[4,10–12]. The final update search was performed in July 2018. Based on a previous compre-
hensive systematic review of the use of placebos or placebo effects in clinical practice in general
[4], involving three of the authors (KL, KM, AS), we knew that no potentially eligible studies
were published before 1997. Therefore, we limited our literature search to publications pub-
lished after 1996.
At least two reviewers independently screened search hits (titles and abstracts) from elec-
tronic databases for potentially eligible publications. References identified in the Google
Scholar citation searches were screened by a single reviewer. Clearly irrelevant search hits were
excluded. Publications considered potentially eligible by at least one reviewer were obtained in
full text. All potentially relevant full text publications were checked formally against the selec-
tion criteria by at least two reviewers. Disagreements were resolved by discussion.
Data collection and quality assessment
Information on country of the survey, population, sampling, definitions, methods and findings
was extracted using a pretested form by at least two reviewers independently. Following a
screening of how data was reported in publications, we extracted the following data to estimate
the frequency of placebo use: number of participating physicians analyzed; number of physi-
cians having used any type of placebo intervention, pure placebos, and non-specific specific
therapies (three intervention classes) at least once in their career, in the last 12 months at least
once, at least monthly, and at least weekly (four timeframes). This resulted in a total of 12 out-
comes (three intervention classes X four different timeframes). In addition we extracted the
number of physicians having used defined placebo interventions (e.g., placebo pills and similar
products, sodium chloride (NaCl) injections or infusions for placebo purposes, antibiotics for
viral infections) in their career. If data for other physician groups beside GPs were reported,
these data were extracted too. If included publications did not report the outcomes listed
above although they were measured or probably measured, we tried to obtain these from the
authors. In addition, one reviewer extracted and classified the reasons for giving placebos as
reported in the included studies.
We assessed quality using six criteria adapted from a widely used tool for observational
studies [13] and the quality assessment tool used in a recent major meta-analysis of cross-sec-
tional surveys [14]: 1) Was the underlying population adequately defined and relevant? 2) Was
the procedure to draw a sample from the population adequate? 3) Is the response rate suffi-
ciently high to rule out selection bias? 4) Did more than 200 GPs participate? 5) Was there
some systematic pre-testing or validation of the questionnaire? 6) Were participating GPs
described? Scoring was operationalized by detailed instructions (see S1 File). We considered
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the questions 1, 2 and 3 as key questions of methodological quality. We further summarized
the answers to sampling (questions 1 and 2) and considered studies with a random sampling
of GPs from an adequately defined (e.g., a country of a region) and sufficiently large popula-
tion (more than 500 GPs) being of high quality. We considered response rates (number of par-
ticipating GPs divided by the number of GP invited) above 0.7 high quality, between 0.4 and
0.7 as moderate quality and below 0.4 as low quality. Disagreements in the extraction and
assessment process were resolved by discussion.
Data analysis
Outcome data on placebo use were extracted as absolute frequencies (number of physicians
meeting a defined criterion). For obtaining proportions, these numbers were divided by the
number of participating physicians. Missing answers were counted as not meeting the crite-
rion (in studies reporting the number of missing observations these were always below 10%).
Proportions were transformed into logits (logarithmic odds) and the respective standard
errors and 95% confidence intervals were calculated for all studies and outcomes. The logits
were used for meta-analyses and back transformed into proportions and percentages after-
wards. Based on the limited available data, we only compared the use of any placebo at any
time in the career between GPs, specialists in private practice, hospital physicians, pediatri-
cians, and internists providing primary care. All comparisons were direct (comparison of GPs
and the other discipline in the same survey). In each study comparing GPs to other groups,
odds ratios with 95% confidence intervals were calculated from the two proportions. The anal-
yses were performed on the log-scale and the meta-analytic results were back transformed to
the odds ratio scale for interpretation. All analyses were random-effects meta-analyses per-
formed using the restricted maximum likelihood estimator. The extent of statistical heteroge-
neity (variation of study findings beyond chance) was tested for significance using Cochrane´s
Q-test and quantified by means of the I2 statistic. All analyses were performed in the open
source statistical environment R with the packages metaphor and ggplot2 [15].
Results
Literature search and selection process
Our literature search identified 674 unique hits (see Fig 1 for a flow chart). Twenty-five poten-
tially relevant articles were formally checked against inclusion criteria. Nine articles were
excluded: five [16–20] reported additional findings or protocols of included studies not pro-
viding information relevant to our review, two did not have GPs as an identifiable subgroup
[21,22], one was a qualitative study [23], and one did not address actual placebo use but a
hypothetic case [24].
Characteristics of included studies
We included 16 studies (reported in 16 publications) for which data on placebo use by GPs
were available [5–7,10,11,25–35]. The 16 studies were published between 2003 and 2017 and
had been performed in 13 different countries (Table 1). Eight studies used high-quality sam-
pling strategies [5–7,10,28–30,33], the remaining eight used less adequate or unclear sampling
methods. Response rates ranged from 16% to 79% in studies with high-quality sampling and
from 8% to 100% in studies with suboptimal sampling methods. Only one study was rated
high quality both regarding for sampling and response rate [29] (see S1 Table for the full rating
of all studies). The number of participating GPs was much higher in studies with high quality
sampling (2,471 in total, range 165 to 783; compared to 520 in total, range 27 to 157). Eight
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studies also surveyed physicians from other medical specialties. Definitions of placebo inter-
ventions (see S2 Table), topics covered, wording of questions, and answer options varied
greatly among included studies creating considerable difficulties for consistent data extraction.
Definitions either included non-specific therapies or separated pure placebos and non-specific
therapies, but no study exclusively focused on pure placebos. Eleven studies presented data on
reasons for prescribing placebo interventions (S3 Table). In the four studies offering this
answer option, 48% to 79% of GPs ticked that they hoped to elicit placebo or psychological
effects. A larger number of studies included a variety of answer options related to patient
expectations and demands, e.g. to calm the patient (agreement between 21% and 58%; 8
Fig 1. Flow diagram of the study selection process.
https://doi.org/10.1371/journal.pone.0202211.g001
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studies), to avoid conflict (29% to 70%; 2 studies), or to handle an unjustified demand of a
patient (9% to 47%; 8 studies). A third group of answer options covered “medical” reasons, e.g.
treating non-specific complaints (22% to 61%; 10 studies), use as a supplement to other thera-
pies (16% to 54%; 7 studies) or using placebo treatment as a diagnostic tool (13% to 60%; 10
studies).
Four (out of a total of seven) studies including also other medical specialties did not report
GP findings separately in the publication, but on request authors either provided subgroup
analyses [28,31] or relevant raw data for re-analysis [25,26]. Full raw data for re-analysis was
available for further three studies [6,7,33].
Frequency of placebo use
Four studies reported data on only one of our 12 outcomes addressing frequency of placebo
use and further nine studies on two to four outcomes. For three studies with a total of 1,310
GPs with available raw data, all 12 outcomes could be calculated. The reported use of any form
of placebo or non-specific therapies varied much more than it could have been expected by
chance alone. The percentage of GPs having used any form of placebo at least once in their
career ranged from 29% to 97% (13 studies), of those having used it at least once in the last
Table 1. Characteristics of included studies (2,911 participating GPs).
First author year
[reference]
Country Population Sampling Response
rate
n
GPs
Other
disciplines
Additional information
from authors
Number outcomes
reported
Babel 2012 [25] Poland Southeast Poland Convenience Unclear 41 Int, Ped Q, raw data subgroups 3 / 4
Babel 2013 [26] Poland Southeast Poland Convenience 78% 50 Int, Ped Q, raw data subgroups 3 / 6
Braga-Simoes 2017
[27]
Portugal Small region
(Matosinhos)
All 74% 93 - Not contacted 4 / 0
Fa¨ssler 2009 [28] Switzerland Regional (Canton
Zurich)
Random 47% 166 Ped Q, subgroup data GP 3 / 2
Fa¨ssler 2011 [29] Switzerland Regional (Canton
Zurich)
Random 79% 232 - Q, additional analyses 1 / 0
Ferentzi 2011 [30] Hungary Country-wide Random 16% 169 - Q 2 / 8
Harris 2015 [31] Canada Academic, country-
wide
Convenience
online
8% 42 Any subgroup data GP 1 / 7
Holt 2009 [32] New
Zealand
Small region Convenience Unclear 157 - No addition. information 4 / 6
Howick 2013 [6] UK Country-wide Random 46% 783 - Q, raw data 12 / 6
Hrobjartsson 2003
[10]
Denmark Country-wide Random 64% 182 Spec, Hosp Not contacted 3 / 4
Kermen 2010 [5] USA Country-wide Random 43% 412 - Could not be contacted 3 / 7
Khan 2015 [35] Pakistan One city
(Faisalabad)
Convenience 92% 80 Gyn, Ped, MO Q 1 / 0
Linde 2014 [7] Germany Country-wide Random 46% 319 Int, Ortho Raw data 12 / 8
Meissner 2012 [33] Germany Regional (Bavaria) Random 55% 208 - Raw data 12 / 6
Nitzan 2004 [11] Israel Unclear Convenience 67% 27 Hosp, Nurses Did not reply 1 / 0
Shah 2009 [34] India One city
(Ahmedabad)
Convenience 100% 30 Hosp, Resid Did not reply 3 / 0
Number of outcome: the first figure indicates the number of frequency outcomes included in meta-analyses (maximum 12) / the second figure the number of specific
intervention outcomes (maximum 11)
only response rates across disciplines available
GP = general practitioners; Gy = gynecologists; Int = internal medicine; MO = medical officers; Ped = pediatrics; Spec = specialists in private practice; Hosp = hospital
physicians; Ortho = orthopedists in private practice; Resid = resident doctors; Q = provided unpublished questionnaire
https://doi.org/10.1371/journal.pone.0202211.t001
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year from 46% to 95% (8 studies), at least monthly from 15% to 89% (10 studies), and at least
weekly from 1% to 75% (8 studies; see upper parts of Fig 2 and S4 Table). Pooled random esti-
mates were 79% (95%CI 68% to 87%), 76% (61% to 86%), 57% (37% to 74%), and 30% (12% to
57%), respectively. However, due to the pronounced heterogeneity (I2 between 96% and 99%),
pooled estimates need to be interpreted with great caution. Four studies provided data on the
use of pure placebos and three on the use of non-specific therapies separately, with three stud-
ies investigating both (Fig 2 and S4 Table, lower parts). The use of non-specific therapies by far
outnumbered the use of pure placebo, but again estimates of usage varied strongly between
studies. For example, the proportion of GPs with use at least monthly varied between 2% and
15% for pure placebos and between 53% and 89% for non-specific therapies, with use at least
weekly between 1% and 3% for pure placebos and between 16% and 75% for non-specific
therapies.
Interventions used as placebos
Eleven studies reported which interventions GPs used as pure placebos or non-specific thera-
pies at least once in their career (see Fig 3). Again, the use of non-specific interventions by far
outperformed the use of pure placebos, but the percentage of users varied greatly across stud-
ies. Saline injections had been used by 2% to 24% of GPs and placebo pills by 3% to 7%.
Instead, use of vitamins was reported by 23% to 75% of GPs, of homeopathic remedies by 33%
to 58%, of antibiotics by 17% to 69%, and of supplements by 35% to 59%. With the exception
of the use of placebo pills (I2 = 0%) study findings varied much more than expected by chance
alone (all I2 > 80%; see S5 Table providing findings of individual studies and details of meta-
analyses).
Comparison with other medical specialties
Seven studies provided data for our comparative analysis of use of any placebo interventions
between disciplines (Table 2). Three studies compared GPs with specialists in private practice.
The two larger studies with high quality sampling found a statistically significantly higher
prevalence of placebo use among GPs while the third smaller study with low quality sampling
did not. Three studies compared GPs and hospital physicians. Results differed strongly with
one larger study with high quality sampling finding higher placebo use among GPs and the
two smaller studies finding no differences. Three small studies compared placebo use among
GPs with that of pediatricians and two with internists providing primary care. Differences
were not statistically significant.
Discussion
Despite highly variable methods and prevalence estimates, the available surveys from a total of
twelve countries provide clear evidence that many GPs use interventions which are considered
placebos in the studies included. Only few (but comparably large) studies provide frequency
estimates on pure placebos and non-specific therapies separately, but together with the data on
which defined interventions have been used as placebos it is obvious that non-specific thera-
pies are used far more often than pure placebos. The data suggest that frequency and patterns
of usage vary considerably between countries. Only few studies compare placebo prescription
across medical specialties. The available findings are inconsistent and inconclusive.
This is the first systematic review and meta-analysis of the use of placebo interventions
among GPs. Based on the experiences from a broader qualitative review of empirical studies of
placebo use in clinical practice published in the year 2010 [4] and thanks to the great coopera-
tion of many of the survey authors who provided original questionnaires (and, if necessary,
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help with translation), additional analyses or raw data, we were able to compile reasonably
comparable data from a quite diverse set of studies. When the literature search for the 2010
review was completed, only three [10,11,28] of the 16 studies now included had been available.
A systematic analysis of the frequency of placebo use had not been performed.
In the past, the publication of placebo surveys among physicians has repeatedly triggered
sensational reports in mass media. For example, based on a survey among US internists pub-
lished in the British Medical Journal [12] on October 23, 2008, the New York Times published
an article titled “Half of Doctors Routinely Prescribe Placebos” [36]. Articles with a similar
message were published in the mass media after surveys among GPs. Do the data compiled in
our review really justify the interpretation of such broad placebo use?
According to a survey in eleven countries [37,38], primary care physicians on average see
between 96 (USA as country with the lowest estimate) and 242 (Germany as country with the
highest estimate) patients per week, with GPs in the UK seeing 130 patients per week. Based
Fig 2. Percentages (95% confidence intervals) of GPs having used a placebo intervention (upper part), a pure
placebo or a non-specific therapy (lower part) at least once in their career (light grey), last year (grey), using it at
least monthly (dark grey) or at least weekly (black). RE = random effects.
https://doi.org/10.1371/journal.pone.0202211.g002
Fig 3. Percentage of GPs having use a defined intervention at least once as a placebo. Graphically presented values are pooled estimates (95% confidence
intervals) n = number of studies in which the intervention was investigated.
https://doi.org/10.1371/journal.pone.0202211.g003
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on these figures, we roughly estimate that GPs have about 500 patient contacts per month in
the UK and 1,000 in Germany. A combination of these figures with the findings of our review
would mean that 2% of UK GPs use a pure placebo in at least 1 of 500 patient contacts [6], and
that 9% to 15% of German GPs do so in at least 1 of 1,000 patient contacts [7,33]. This can
hardly be considered frequent use. What seems to be used “routinely” by many GPs are non-
specific therapies. Using the same approximation as for pure placebo, we estimate that 89% of
GPs in the UK use a non-specific therapy in at least 1 of 500 patient contacts, and that between
57% and 69% of German GPs do so in at least 1 of 1,000 patient contacts.
However, is it really adequate to interpret the widespread use of non-specific therapies as
use of placebos? The main argument for doing so is nicely summarized by Miller and Colloca:
“. . . what makes substances or interventions count as placebos is the lack of specific efficacy in
treating a specific patient’s condition based on the inherent properties of the treatment” [39].
However, there are several problems with this view. First, when hearing the word ‘placebo’
both physicians [16,23] and patients [29] usually intuitively think of pure placebos or words
attributed to pure placebos (such as “inert”). As a consequence, many lay persons and physi-
cians are surprised when they hear about the high prevalence of “placebo use”. Second, even
from the perspective of research, it is not always clear whether a treatment has “specific effi-
cacy” or not. For patients and practicing physicians, own beliefs and experiences strongly
influence what is considered specifically active or not. For example, among German physicians
the belief whether treatments such as acupuncture, homeopathy, herbs or osteopathy have
Table 2. Placebo use (ever of of any form of placebo) among GP compared to other disciplines.
First author Year (Country) N use N no use N use N no use OR (95%CI)
GPs Specialists private practice
Hrobjartsson 2003 (DEN) 157 25 56 80 8.97 (5.21, 15.44)
Linde 2014 (GER) 252 67 327 289 3.32 (2.43, 4.54)
Khan 2015 (PK) 51 29 64 30 0.82 (0.44, 1.55)
Pooled (RE) 2.94 (0.77, 11.15)
Heterogeneity: Q = 31.71, df = 2, p = <0.01, I2 = 96%
GPs Hospital physicians
Hrobjartsson 2003 (DEN) 157 25 100 85 5.34 (3.20, 8.90)
Nitzan 2004 (ISR) 12 15 19 12 0.51 (0.18, 1.44)
Shah 2009 (IND) 27 3 53 7 1.19 (0.28, 4.97)
Pooled 1.59 (0.37, 6.78)
Heterogeneity: Q = 17.6, df = 2, p<0.01, I2 = 85%
GPs Pediatricians (primary
care)
Babel 2012 (POL) 39 2 46 8 3.39 (0.68, 16.92)
Babel 2013 (POL) 41 9 34 14 1.88 (0.72, 4.86)
Khan 2015 (PK) 51 29 48 16 0.59 (0.28, 1.21)
Pooled 2.19 (0.96, 4.97)
Heterogeneity: Q = 5.94, df = 2, p = 0.05, I2 = 66%
GPs Internists (primary care)
Babel 2012 (POL) 39 2 78 17 4.25 (0.93, 19.33)
Babel 2013 (POL) 41 9 60 13 0.99 (0.39, 2.52)
Pooled 1.81 (0.44, 7.39)
Heterogeneity: Q = 2.58, df = 1, p = 0.11, I2 = 61%
OR = odds ratio; CI = confidence interval
https://doi.org/10.1371/journal.pone.0202211.t002
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effects over placebo varies strongly [40]. It seems very likely that subjective views and the
wording of questions and answer options strongly influence survey findings on the use of non-
specific therapies [4,8,9]. This is related to the third challenge. In our view, placebo researchers
often misinterpret why physicians prescribe placebos in general and non-specific treatments
in particular. Most researchers administering surveys assume implicitly or even explicitly that
physicians use “placebos” mainly for eliciting placebo effects. For example, in the BMJ 2008
survey, the authors state that “placebo treatments include . . . physiologically active agents,
such as vitamins or antibiotics, that the physicians prescribe solely or primarily to promote
positive psychological effects” [12]. Only few respondents in the quantitative surveys actively
argue against such definitions (but some do; see, for example [16]). However, there are reasons
to assume that promoting placebo effects is more often an a posteriori justification than an a
priori reason. For example, when checking qualitative studies on reasons for antibiotic pre-
scribing in viral infections–a typical example for an impure placebo in surveys—included in a
systematic review [41], we could not find a single study mentioning the word placebo or a
related motive. Reported important reasons for antibiotic prescribing are perceived pressure
by patients, lack of time, preserving an unstable patient-physician relationship, or diagnostic
uncertainty. Qualitative studies on “irrational” [42], “nonscientific” [43] or otherwise difficult
prescribing [44,45] suggest that the use of non-specific therapies is a strategy to deal with a
variety of challenges in busy routine practice. Most of the reasons for placebo use reported in
the studies included in our review strengthen this interpretation. Due to its conceptual prob-
lems Louhiala et al. consider the concept of impure placebos (which we call non-specific thera-
pies in this paper) as useless, scientifically unsound and potentially harmful [9].
Hrobjartsson has argued that in the majority of cases physicians use (mostly impure) place-
bos for “convenience”, either to get a patient stop complaining or to avoid conflict [1]. Instead,
Louhiala et al. believe that at least some of what in surveys is called impure placebo (for exam-
ple, positive suggestions) actually can be considered “good doctoring” [9]. We are aware that
the term non-specific therapies which we use in this review suffers from similar conceptual
problems as the term impure placebo. But at least, it greatly reduces the risk of a simplistic
interpretation of a complex phenomenon.
Currently, there is considerable interest in the prescription of (pure) placebos without
deception (sometimes referred to as “open-label placebo” [46]). The idea is that patients are
informed about the placebo effect and, after giving informed consent, openly receive an inert
intervention. This is a fascinating approach respecting the autonomy of the patient and the
professional integrity of the physician. The (few) available randomized trials suggest it can be
feasible and effective [47]. It is clearly desirable to test and possibly implement this strategy on
a larger scale in general practice. However, there might be a long way to go as placebo without
deception might not be a solution to many of the problems in which GPs currently use non-
specific therapies (e.g., when a patient with a cold demands an antibiotic).
Due to diversity of the studies included in our review regarding main focus, definitions,
questionnaires, sampling methods, response rates, sample sizes and other quality issues the fre-
quency estimates found in our review should only be considered crude indicators. The statisti-
cal heterogeneity of almost all of our pooled estimates is very high, but given the limited
number of studies contributing to meta-analyses, problems in reliably operationalizing poten-
tial confounders, and the unclear interactions between the confounders we refrained from per-
forming meta-regression analyses. Based on the data it seems likely that the use of placebos
varies between countries regarding what is actually done (e.g., more German GPs seem to use
pure placebos than GPs from the UK), but it also seems plausible that there are cultural differ-
ences regarding what is considered a non-specific therapy (e.g., GPs from the UK may follow
more what is evidence-based, while German GPs may have a stronger belief in their own
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experience). Furthermore, it is likely that definitions and methods of asking make a difference.
For example, one of the included studies [25] showed that using the term “non-specific thera-
pies” instead of “placebo” was associated with higher placebo use estimates although the defini-
tion of the terms was exactly the same. Also, we assume that asking to rate a long list of
examples of non-specific therapies (as in the large UK survey [6]) is associated with higher esti-
mates than a global question. Finally, it is also possible that selection bias differs between
countries.
In conclusion, high prevalence estimates of placebo use among GPs are primarily driven by
the frequent use of non-specific therapies; pure placebos are used rarely. It seems likely that in
the majority of cases non-specific therapies are not primarily used to elicit placebo effects but
to cope with difficult situations in busy routine practice. In the view of the authors it can be
misleading to subsume the use of non-specific therapies simply as ‘placebo use’. The issue of
placebo and non-specific interventions should be addressed in GP training programs. Future
research is needed to better understand why many GPs are using such interventions. Also,
investigations should be conducted about how GPs, who do not use such strategies (or claim
to do so), cope with the challenges in busy daily practice. We believe that such research pri-
marily should be qualitative. International, large-scale surveys are needed to be able to directly
compare the differences in placebo prescription behavior of GPs (and across medical disci-
plines) between countries. However, such surveys should carefully consider the major prob-
lems of the concept of impure placebos/non-specific therapies in the planning phase, avoid
suggestive wording in questionnaires, and carefully discuss the limitations of the findings for
avoiding simplistic interpretations in the mass media.
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